0
  • Category
  • Region
U.S. (TOLL FREE)
+1 (315) 215-3225
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Peripheral Decarboxylase Inhibitors Market Research Report 2025
Published Date: March 2025
|
Report Code: QYRE-Auto-19P19231
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Peripheral Decarboxylase Inhibitors Market Research Report 2025
BUY CHAPTERS

Global Peripheral Decarboxylase Inhibitors Market Research Report 2025

Code: QYRE-Auto-19P19231
Report
March 2025
Pages:92
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Peripheral Decarboxylase Inhibitors Market Size

The global market for Peripheral Decarboxylase Inhibitors was valued at US$ 1669 million in the year 2024 and is projected to reach a revised size of US$ 2363 million by 2031, growing at a CAGR of 5.1% during the forecast period.

Peripheral Decarboxylase Inhibitors Market

Peripheral Decarboxylase Inhibitors Market

Peripheral Decarboxylase Inhibitors (PDIs) are a class of drugs that selectively inhibit the enzyme aromatic L-amino acid decarboxylase (AADC) in the peripheral nervous system. This enzyme is responsible for converting levodopa into dopamine before it reaches the brain. By inhibiting this peripheral conversion, PDIs help increase the amount of levodopa that crosses the blood-brain barrier, enhancing its effectiveness in treating Parkinson’s disease while reducing peripheral side effects such as nausea and low blood pressure. Common PDIs include carbidopa and benserazide, which are often combined with levodopa in Parkinson’s therapy.
North American market for Peripheral Decarboxylase Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Peripheral Decarboxylase Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Peripheral Decarboxylase Inhibitors include Amneal Pharmaceuticals, AbbVie, Roche, Roemmers SAICF, Organon Pharma, Teva, Mayne Pharma, Shanghai Fuda, Sun Pharmaceutical, Psicofarma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Peripheral Decarboxylase Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peripheral Decarboxylase Inhibitors.
The Peripheral Decarboxylase Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peripheral Decarboxylase Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peripheral Decarboxylase Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Peripheral Decarboxylase Inhibitors Market Report

Report Metric Details
Report Name Peripheral Decarboxylase Inhibitors Market
Accounted market size in year US$ 1669 million
Forecasted market size in 2031 US$ 2363 million
CAGR 5.1%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Dopamine
  • Carbidopa
Segment by Application
  • Hospital
  • Retail Pharmacy
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Amneal Pharmaceuticals, AbbVie, Roche, Roemmers SAICF, Organon Pharma, Teva, Mayne Pharma, Shanghai Fuda, Sun Pharmaceutical, Psicofarma, Pfizer, Eastpharma, Apotex, Torrent Pharmaceuticals, Novartis
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Peripheral Decarboxylase Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Peripheral Decarboxylase Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Peripheral Decarboxylase Inhibitors Market growing?

Ans: The Peripheral Decarboxylase Inhibitors Market witnessing a CAGR of 5.1% during the forecast period 2025-2031.

What is the Peripheral Decarboxylase Inhibitors Market size in 2031?

Ans: The Peripheral Decarboxylase Inhibitors Market size in 2031 will be US$ 2363 million.

Who are the main players in the Peripheral Decarboxylase Inhibitors Market report?

Ans: The main players in the Peripheral Decarboxylase Inhibitors Market are Amneal Pharmaceuticals, AbbVie, Roche, Roemmers SAICF, Organon Pharma, Teva, Mayne Pharma, Shanghai Fuda, Sun Pharmaceutical, Psicofarma, Pfizer, Eastpharma, Apotex, Torrent Pharmaceuticals, Novartis

What are the Application segmentation covered in the Peripheral Decarboxylase Inhibitors Market report?

Ans: The Applications covered in the Peripheral Decarboxylase Inhibitors Market report are Hospital, Retail Pharmacy, Other

What are the Type segmentation covered in the Peripheral Decarboxylase Inhibitors Market report?

Ans: The Types covered in the Peripheral Decarboxylase Inhibitors Market report are Dopamine, Carbidopa

1 Peripheral Decarboxylase Inhibitors Market Overview
1.1 Product Definition
1.2 Peripheral Decarboxylase Inhibitors by Type
1.2.1 Global Peripheral Decarboxylase Inhibitors Market Value Comparison by Type (2024 VS 2031)
1.2.2 Dopamine
1.2.3 Carbidopa
1.3 Peripheral Decarboxylase Inhibitors by Application
1.3.1 Global Peripheral Decarboxylase Inhibitors Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Global Peripheral Decarboxylase Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Peripheral Decarboxylase Inhibitors Revenue 2020-2031
1.4.2 Global Peripheral Decarboxylase Inhibitors Sales 2020-2031
1.4.3 Global Peripheral Decarboxylase Inhibitors Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Peripheral Decarboxylase Inhibitors Market Competition by Manufacturers
2.1 Global Peripheral Decarboxylase Inhibitors Sales Market Share by Manufacturers (2020-2025)
2.2 Global Peripheral Decarboxylase Inhibitors Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Peripheral Decarboxylase Inhibitors Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Peripheral Decarboxylase Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Peripheral Decarboxylase Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Peripheral Decarboxylase Inhibitors, Product Type & Application
2.7 Global Key Manufacturers of Peripheral Decarboxylase Inhibitors, Date of Enter into This Industry
2.8 Global Peripheral Decarboxylase Inhibitors Market Competitive Situation and Trends
2.8.1 Global Peripheral Decarboxylase Inhibitors Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Peripheral Decarboxylase Inhibitors Players Market Share by Revenue
2.8.3 Global Peripheral Decarboxylase Inhibitors Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Peripheral Decarboxylase Inhibitors Market Scenario by Region
3.1 Global Peripheral Decarboxylase Inhibitors Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Peripheral Decarboxylase Inhibitors Sales by Region: 2020-2031
3.2.1 Global Peripheral Decarboxylase Inhibitors Sales by Region: 2020-2025
3.2.2 Global Peripheral Decarboxylase Inhibitors Sales by Region: 2026-2031
3.3 Global Peripheral Decarboxylase Inhibitors Revenue by Region: 2020-2031
3.3.1 Global Peripheral Decarboxylase Inhibitors Revenue by Region: 2020-2025
3.3.2 Global Peripheral Decarboxylase Inhibitors Revenue by Region: 2026-2031
3.4 North America Peripheral Decarboxylase Inhibitors Market Facts & Figures by Country
3.4.1 North America Peripheral Decarboxylase Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Peripheral Decarboxylase Inhibitors Sales by Country (2020-2031)
3.4.3 North America Peripheral Decarboxylase Inhibitors Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Peripheral Decarboxylase Inhibitors Market Facts & Figures by Country
3.5.1 Europe Peripheral Decarboxylase Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Peripheral Decarboxylase Inhibitors Sales by Country (2020-2031)
3.5.3 Europe Peripheral Decarboxylase Inhibitors Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Peripheral Decarboxylase Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific Peripheral Decarboxylase Inhibitors Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Peripheral Decarboxylase Inhibitors Sales by Region (2020-2031)
3.6.3 Asia Pacific Peripheral Decarboxylase Inhibitors Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Peripheral Decarboxylase Inhibitors Market Facts & Figures by Country
3.7.1 Latin America Peripheral Decarboxylase Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Peripheral Decarboxylase Inhibitors Sales by Country (2020-2031)
3.7.3 Latin America Peripheral Decarboxylase Inhibitors Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Peripheral Decarboxylase Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa Peripheral Decarboxylase Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Peripheral Decarboxylase Inhibitors Sales by Country (2020-2031)
3.8.3 Middle East and Africa Peripheral Decarboxylase Inhibitors Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Peripheral Decarboxylase Inhibitors Sales by Type (2020-2031)
4.1.1 Global Peripheral Decarboxylase Inhibitors Sales by Type (2020-2025)
4.1.2 Global Peripheral Decarboxylase Inhibitors Sales by Type (2026-2031)
4.1.3 Global Peripheral Decarboxylase Inhibitors Sales Market Share by Type (2020-2031)
4.2 Global Peripheral Decarboxylase Inhibitors Revenue by Type (2020-2031)
4.2.1 Global Peripheral Decarboxylase Inhibitors Revenue by Type (2020-2025)
4.2.2 Global Peripheral Decarboxylase Inhibitors Revenue by Type (2026-2031)
4.2.3 Global Peripheral Decarboxylase Inhibitors Revenue Market Share by Type (2020-2031)
4.3 Global Peripheral Decarboxylase Inhibitors Price by Type (2020-2031)
5 Segment by Application
5.1 Global Peripheral Decarboxylase Inhibitors Sales by Application (2020-2031)
5.1.1 Global Peripheral Decarboxylase Inhibitors Sales by Application (2020-2025)
5.1.2 Global Peripheral Decarboxylase Inhibitors Sales by Application (2026-2031)
5.1.3 Global Peripheral Decarboxylase Inhibitors Sales Market Share by Application (2020-2031)
5.2 Global Peripheral Decarboxylase Inhibitors Revenue by Application (2020-2031)
5.2.1 Global Peripheral Decarboxylase Inhibitors Revenue by Application (2020-2025)
5.2.2 Global Peripheral Decarboxylase Inhibitors Revenue by Application (2026-2031)
5.2.3 Global Peripheral Decarboxylase Inhibitors Revenue Market Share by Application (2020-2031)
5.3 Global Peripheral Decarboxylase Inhibitors Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Amneal Pharmaceuticals
6.1.1 Amneal Pharmaceuticals Company Information
6.1.2 Amneal Pharmaceuticals Description and Business Overview
6.1.3 Amneal Pharmaceuticals Peripheral Decarboxylase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Amneal Pharmaceuticals Peripheral Decarboxylase Inhibitors Product Portfolio
6.1.5 Amneal Pharmaceuticals Recent Developments/Updates
6.2 AbbVie
6.2.1 AbbVie Company Information
6.2.2 AbbVie Description and Business Overview
6.2.3 AbbVie Peripheral Decarboxylase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.2.4 AbbVie Peripheral Decarboxylase Inhibitors Product Portfolio
6.2.5 AbbVie Recent Developments/Updates
6.3 Roche
6.3.1 Roche Company Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Peripheral Decarboxylase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Roche Peripheral Decarboxylase Inhibitors Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Roemmers SAICF
6.4.1 Roemmers SAICF Company Information
6.4.2 Roemmers SAICF Description and Business Overview
6.4.3 Roemmers SAICF Peripheral Decarboxylase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Roemmers SAICF Peripheral Decarboxylase Inhibitors Product Portfolio
6.4.5 Roemmers SAICF Recent Developments/Updates
6.5 Organon Pharma
6.5.1 Organon Pharma Company Information
6.5.2 Organon Pharma Description and Business Overview
6.5.3 Organon Pharma Peripheral Decarboxylase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Organon Pharma Peripheral Decarboxylase Inhibitors Product Portfolio
6.5.5 Organon Pharma Recent Developments/Updates
6.6 Teva
6.6.1 Teva Company Information
6.6.2 Teva Description and Business Overview
6.6.3 Teva Peripheral Decarboxylase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Teva Peripheral Decarboxylase Inhibitors Product Portfolio
6.6.5 Teva Recent Developments/Updates
6.7 Mayne Pharma
6.7.1 Mayne Pharma Company Information
6.7.2 Mayne Pharma Description and Business Overview
6.7.3 Mayne Pharma Peripheral Decarboxylase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Mayne Pharma Peripheral Decarboxylase Inhibitors Product Portfolio
6.7.5 Mayne Pharma Recent Developments/Updates
6.8 Shanghai Fuda
6.8.1 Shanghai Fuda Company Information
6.8.2 Shanghai Fuda Description and Business Overview
6.8.3 Shanghai Fuda Peripheral Decarboxylase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Shanghai Fuda Peripheral Decarboxylase Inhibitors Product Portfolio
6.8.5 Shanghai Fuda Recent Developments/Updates
6.9 Sun Pharmaceutical
6.9.1 Sun Pharmaceutical Company Information
6.9.2 Sun Pharmaceutical Description and Business Overview
6.9.3 Sun Pharmaceutical Peripheral Decarboxylase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Sun Pharmaceutical Peripheral Decarboxylase Inhibitors Product Portfolio
6.9.5 Sun Pharmaceutical Recent Developments/Updates
6.10 Psicofarma
6.10.1 Psicofarma Company Information
6.10.2 Psicofarma Description and Business Overview
6.10.3 Psicofarma Peripheral Decarboxylase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Psicofarma Peripheral Decarboxylase Inhibitors Product Portfolio
6.10.5 Psicofarma Recent Developments/Updates
6.11 Pfizer
6.11.1 Pfizer Company Information
6.11.2 Pfizer Description and Business Overview
6.11.3 Pfizer Peripheral Decarboxylase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Pfizer Peripheral Decarboxylase Inhibitors Product Portfolio
6.11.5 Pfizer Recent Developments/Updates
6.12 Eastpharma
6.12.1 Eastpharma Company Information
6.12.2 Eastpharma Description and Business Overview
6.12.3 Eastpharma Peripheral Decarboxylase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Eastpharma Peripheral Decarboxylase Inhibitors Product Portfolio
6.12.5 Eastpharma Recent Developments/Updates
6.13 Apotex
6.13.1 Apotex Company Information
6.13.2 Apotex Description and Business Overview
6.13.3 Apotex Peripheral Decarboxylase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Apotex Peripheral Decarboxylase Inhibitors Product Portfolio
6.13.5 Apotex Recent Developments/Updates
6.14 Torrent Pharmaceuticals
6.14.1 Torrent Pharmaceuticals Company Information
6.14.2 Torrent Pharmaceuticals Description and Business Overview
6.14.3 Torrent Pharmaceuticals Peripheral Decarboxylase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Torrent Pharmaceuticals Peripheral Decarboxylase Inhibitors Product Portfolio
6.14.5 Torrent Pharmaceuticals Recent Developments/Updates
6.15 Novartis
6.15.1 Novartis Company Information
6.15.2 Novartis Description and Business Overview
6.15.3 Novartis Peripheral Decarboxylase Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Novartis Peripheral Decarboxylase Inhibitors Product Portfolio
6.15.5 Novartis Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Peripheral Decarboxylase Inhibitors Industry Chain Analysis
7.2 Peripheral Decarboxylase Inhibitors Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Peripheral Decarboxylase Inhibitors Production Mode & Process Analysis
7.4 Peripheral Decarboxylase Inhibitors Sales and Marketing
7.4.1 Peripheral Decarboxylase Inhibitors Sales Channels
7.4.2 Peripheral Decarboxylase Inhibitors Distributors
7.5 Peripheral Decarboxylase Inhibitors Customer Analysis
8 Peripheral Decarboxylase Inhibitors Market Dynamics
8.1 Peripheral Decarboxylase Inhibitors Industry Trends
8.2 Peripheral Decarboxylase Inhibitors Market Drivers
8.3 Peripheral Decarboxylase Inhibitors Market Challenges
8.4 Peripheral Decarboxylase Inhibitors Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Peripheral Decarboxylase Inhibitors Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Peripheral Decarboxylase Inhibitors Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Peripheral Decarboxylase Inhibitors Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Peripheral Decarboxylase Inhibitors Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Peripheral Decarboxylase Inhibitors Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Peripheral Decarboxylase Inhibitors Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Peripheral Decarboxylase Inhibitors Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Peripheral Decarboxylase Inhibitors Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Peripheral Decarboxylase Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Peripheral Decarboxylase Inhibitors, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Peripheral Decarboxylase Inhibitors, Product Type & Application
 Table 12. Global Key Manufacturers of Peripheral Decarboxylase Inhibitors, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Peripheral Decarboxylase Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peripheral Decarboxylase Inhibitors as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Peripheral Decarboxylase Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Peripheral Decarboxylase Inhibitors Sales by Region (2020-2025) & (K Units)
 Table 18. Global Peripheral Decarboxylase Inhibitors Sales Market Share by Region (2020-2025)
 Table 19. Global Peripheral Decarboxylase Inhibitors Sales by Region (2026-2031) & (K Units)
 Table 20. Global Peripheral Decarboxylase Inhibitors Sales Market Share by Region (2026-2031)
 Table 21. Global Peripheral Decarboxylase Inhibitors Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Peripheral Decarboxylase Inhibitors Revenue Market Share by Region (2020-2025)
 Table 23. Global Peripheral Decarboxylase Inhibitors Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Peripheral Decarboxylase Inhibitors Revenue Market Share by Region (2026-2031)
 Table 25. North America Peripheral Decarboxylase Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Peripheral Decarboxylase Inhibitors Sales by Country (2020-2025) & (K Units)
 Table 27. North America Peripheral Decarboxylase Inhibitors Sales by Country (2026-2031) & (K Units)
 Table 28. North America Peripheral Decarboxylase Inhibitors Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Peripheral Decarboxylase Inhibitors Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Peripheral Decarboxylase Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Peripheral Decarboxylase Inhibitors Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Peripheral Decarboxylase Inhibitors Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Peripheral Decarboxylase Inhibitors Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Peripheral Decarboxylase Inhibitors Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Peripheral Decarboxylase Inhibitors Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Peripheral Decarboxylase Inhibitors Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Peripheral Decarboxylase Inhibitors Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Peripheral Decarboxylase Inhibitors Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Peripheral Decarboxylase Inhibitors Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Peripheral Decarboxylase Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Peripheral Decarboxylase Inhibitors Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Peripheral Decarboxylase Inhibitors Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Peripheral Decarboxylase Inhibitors Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Peripheral Decarboxylase Inhibitors Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Peripheral Decarboxylase Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Peripheral Decarboxylase Inhibitors Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Peripheral Decarboxylase Inhibitors Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Peripheral Decarboxylase Inhibitors Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Peripheral Decarboxylase Inhibitors Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Peripheral Decarboxylase Inhibitors Sales (K Units) by Type (2020-2025)
 Table 51. Global Peripheral Decarboxylase Inhibitors Sales (K Units) by Type (2026-2031)
 Table 52. Global Peripheral Decarboxylase Inhibitors Sales Market Share by Type (2020-2025)
 Table 53. Global Peripheral Decarboxylase Inhibitors Sales Market Share by Type (2026-2031)
 Table 54. Global Peripheral Decarboxylase Inhibitors Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Peripheral Decarboxylase Inhibitors Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Peripheral Decarboxylase Inhibitors Revenue Market Share by Type (2020-2025)
 Table 57. Global Peripheral Decarboxylase Inhibitors Revenue Market Share by Type (2026-2031)
 Table 58. Global Peripheral Decarboxylase Inhibitors Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Peripheral Decarboxylase Inhibitors Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Peripheral Decarboxylase Inhibitors Sales (K Units) by Application (2020-2025)
 Table 61. Global Peripheral Decarboxylase Inhibitors Sales (K Units) by Application (2026-2031)
 Table 62. Global Peripheral Decarboxylase Inhibitors Sales Market Share by Application (2020-2025)
 Table 63. Global Peripheral Decarboxylase Inhibitors Sales Market Share by Application (2026-2031)
 Table 64. Global Peripheral Decarboxylase Inhibitors Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Peripheral Decarboxylase Inhibitors Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Peripheral Decarboxylase Inhibitors Revenue Market Share by Application (2020-2025)
 Table 67. Global Peripheral Decarboxylase Inhibitors Revenue Market Share by Application (2026-2031)
 Table 68. Global Peripheral Decarboxylase Inhibitors Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Peripheral Decarboxylase Inhibitors Price (US$/Unit) by Application (2026-2031)
 Table 70. Amneal Pharmaceuticals Company Information
 Table 71. Amneal Pharmaceuticals Description and Business Overview
 Table 72. Amneal Pharmaceuticals Peripheral Decarboxylase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Amneal Pharmaceuticals Peripheral Decarboxylase Inhibitors Product
 Table 74. Amneal Pharmaceuticals Recent Developments/Updates
 Table 75. AbbVie Company Information
 Table 76. AbbVie Description and Business Overview
 Table 77. AbbVie Peripheral Decarboxylase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. AbbVie Peripheral Decarboxylase Inhibitors Product
 Table 79. AbbVie Recent Developments/Updates
 Table 80. Roche Company Information
 Table 81. Roche Description and Business Overview
 Table 82. Roche Peripheral Decarboxylase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Roche Peripheral Decarboxylase Inhibitors Product
 Table 84. Roche Recent Developments/Updates
 Table 85. Roemmers SAICF Company Information
 Table 86. Roemmers SAICF Description and Business Overview
 Table 87. Roemmers SAICF Peripheral Decarboxylase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Roemmers SAICF Peripheral Decarboxylase Inhibitors Product
 Table 89. Roemmers SAICF Recent Developments/Updates
 Table 90. Organon Pharma Company Information
 Table 91. Organon Pharma Description and Business Overview
 Table 92. Organon Pharma Peripheral Decarboxylase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Organon Pharma Peripheral Decarboxylase Inhibitors Product
 Table 94. Organon Pharma Recent Developments/Updates
 Table 95. Teva Company Information
 Table 96. Teva Description and Business Overview
 Table 97. Teva Peripheral Decarboxylase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Teva Peripheral Decarboxylase Inhibitors Product
 Table 99. Teva Recent Developments/Updates
 Table 100. Mayne Pharma Company Information
 Table 101. Mayne Pharma Description and Business Overview
 Table 102. Mayne Pharma Peripheral Decarboxylase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Mayne Pharma Peripheral Decarboxylase Inhibitors Product
 Table 104. Mayne Pharma Recent Developments/Updates
 Table 105. Shanghai Fuda Company Information
 Table 106. Shanghai Fuda Description and Business Overview
 Table 107. Shanghai Fuda Peripheral Decarboxylase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Shanghai Fuda Peripheral Decarboxylase Inhibitors Product
 Table 109. Shanghai Fuda Recent Developments/Updates
 Table 110. Sun Pharmaceutical Company Information
 Table 111. Sun Pharmaceutical Description and Business Overview
 Table 112. Sun Pharmaceutical Peripheral Decarboxylase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Sun Pharmaceutical Peripheral Decarboxylase Inhibitors Product
 Table 114. Sun Pharmaceutical Recent Developments/Updates
 Table 115. Psicofarma Company Information
 Table 116. Psicofarma Description and Business Overview
 Table 117. Psicofarma Peripheral Decarboxylase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Psicofarma Peripheral Decarboxylase Inhibitors Product
 Table 119. Psicofarma Recent Developments/Updates
 Table 120. Pfizer Company Information
 Table 121. Pfizer Description and Business Overview
 Table 122. Pfizer Peripheral Decarboxylase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Pfizer Peripheral Decarboxylase Inhibitors Product
 Table 124. Pfizer Recent Developments/Updates
 Table 125. Eastpharma Company Information
 Table 126. Eastpharma Description and Business Overview
 Table 127. Eastpharma Peripheral Decarboxylase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Eastpharma Peripheral Decarboxylase Inhibitors Product
 Table 129. Eastpharma Recent Developments/Updates
 Table 130. Apotex Company Information
 Table 131. Apotex Description and Business Overview
 Table 132. Apotex Peripheral Decarboxylase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Apotex Peripheral Decarboxylase Inhibitors Product
 Table 134. Apotex Recent Developments/Updates
 Table 135. Torrent Pharmaceuticals Company Information
 Table 136. Torrent Pharmaceuticals Description and Business Overview
 Table 137. Torrent Pharmaceuticals Peripheral Decarboxylase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Torrent Pharmaceuticals Peripheral Decarboxylase Inhibitors Product
 Table 139. Torrent Pharmaceuticals Recent Developments/Updates
 Table 140. Novartis Company Information
 Table 141. Novartis Description and Business Overview
 Table 142. Novartis Peripheral Decarboxylase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. Novartis Peripheral Decarboxylase Inhibitors Product
 Table 144. Novartis Recent Developments/Updates
 Table 145. Key Raw Materials Lists
 Table 146. Raw Materials Key Suppliers Lists
 Table 147. Peripheral Decarboxylase Inhibitors Distributors List
 Table 148. Peripheral Decarboxylase Inhibitors Customers List
 Table 149. Peripheral Decarboxylase Inhibitors Market Trends
 Table 150. Peripheral Decarboxylase Inhibitors Market Drivers
 Table 151. Peripheral Decarboxylase Inhibitors Market Challenges
 Table 152. Peripheral Decarboxylase Inhibitors Market Restraints
 Table 153. Research Programs/Design for This Report
 Table 154. Key Data Information from Secondary Sources
 Table 155. Key Data Information from Primary Sources
 Table 156. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Peripheral Decarboxylase Inhibitors
 Figure 2. Global Peripheral Decarboxylase Inhibitors Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Peripheral Decarboxylase Inhibitors Market Share by Type: 2024 & 2031
 Figure 4. Dopamine Product Picture
 Figure 5. Carbidopa Product Picture
 Figure 6. Global Peripheral Decarboxylase Inhibitors Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Peripheral Decarboxylase Inhibitors Market Share by Application: 2024 & 2031
 Figure 8. Hospital
 Figure 9. Retail Pharmacy
 Figure 10. Other
 Figure 11. Global Peripheral Decarboxylase Inhibitors Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Peripheral Decarboxylase Inhibitors Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Peripheral Decarboxylase Inhibitors Sales (2020-2031) & (K Units)
 Figure 14. Global Peripheral Decarboxylase Inhibitors Average Price (US$/Unit) & (2020-2031)
 Figure 15. Peripheral Decarboxylase Inhibitors Report Years Considered
 Figure 16. Peripheral Decarboxylase Inhibitors Sales Share by Manufacturers in 2024
 Figure 17. Global Peripheral Decarboxylase Inhibitors Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Peripheral Decarboxylase Inhibitors Players: Market Share by Revenue in Peripheral Decarboxylase Inhibitors in 2024
 Figure 19. Peripheral Decarboxylase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Peripheral Decarboxylase Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Peripheral Decarboxylase Inhibitors Sales Market Share by Country (2020-2031)
 Figure 22. North America Peripheral Decarboxylase Inhibitors Revenue Market Share by Country (2020-2031)
 Figure 23. United States Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Peripheral Decarboxylase Inhibitors Sales Market Share by Country (2020-2031)
 Figure 26. Europe Peripheral Decarboxylase Inhibitors Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Peripheral Decarboxylase Inhibitors Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Peripheral Decarboxylase Inhibitors Revenue Market Share by Region (2020-2031)
 Figure 34. China Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Southeast Asia Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Latin America Peripheral Decarboxylase Inhibitors Sales Market Share by Country (2020-2031)
 Figure 42. Latin America Peripheral Decarboxylase Inhibitors Revenue Market Share by Country (2020-2031)
 Figure 43. Mexico Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Brazil Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Argentina Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Colombia Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Middle East and Africa Peripheral Decarboxylase Inhibitors Sales Market Share by Country (2020-2031)
 Figure 48. Middle East and Africa Peripheral Decarboxylase Inhibitors Revenue Market Share by Country (2020-2031)
 Figure 49. Turkey Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Saudi Arabia Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. UAE Peripheral Decarboxylase Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Global Sales Market Share of Peripheral Decarboxylase Inhibitors by Type (2020-2031)
 Figure 53. Global Revenue Market Share of Peripheral Decarboxylase Inhibitors by Type (2020-2031)
 Figure 54. Global Peripheral Decarboxylase Inhibitors Price (US$/Unit) by Type (2020-2031)
 Figure 55. Global Sales Market Share of Peripheral Decarboxylase Inhibitors by Application (2020-2031)
 Figure 56. Global Revenue Market Share of Peripheral Decarboxylase Inhibitors by Application (2020-2031)
 Figure 57. Global Peripheral Decarboxylase Inhibitors Price (US$/Unit) by Application (2020-2031)
 Figure 58. Peripheral Decarboxylase Inhibitors Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS